Determinants of elevated levels of natural anticoagulants in healthy subjects

Advances in Clinical and Experimental Medicine

Volumn 24, Issue 5, 2015, Pages 791-800

  Koscielniak, Barbara ^a   Wypasek, Ewa ^b   Undas, Anetta ^b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antithrombin; Protein C; Protein S

Indexed keywords

ANTITHROMBIN; C REACTIVE PROTEIN; PROTEIN C; PROTEIN S; ANTICOAGULANT AGENT; LIPID;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD EXAMINATION; BODY MASS; CARDIOVASCULAR DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; GENETIC SCREENING; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; IMMUNOASSAY; IMMUNOLOGICAL PROCEDURES; IMMUNOTURBIDIMETRIC ASSAY; LABORATORY TEST; MALE; NORMAL HUMAN; OBESITY; RISK FACTOR; VENOUS THROMBOEMBOLISM; BLOOD; METABOLISM; MIDDLE AGED; PHOTOMETRY; PROCEDURES; STATISTICAL MODEL; YOUNG ADULT;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROTEIN C; PROTEIN S; YOUNG ADULT;

EID: 84954548315     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/44361     Document Type: Article

References (30)

1. Griffin JH, Fernández JA, Gale A.J., Mosnier LO: Activated protein C. J Thromb Haemost 2007, 5, 73-80.
2. Xu J, Esmon NL, Esmon CT: Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 1999, 274, 6704-6710.
3. Wypasek E, Undas A: Protein C and protein S deficiency - practical diagnostic issues. Adv Clin Exp Med 2013, 22, 459-467.
4. Liu L, Dewar L, Song Y., Kulczycky M, Blajchman MA, Fenton J.W., Andrew M., Delorme M, Ginsberg J, Preissner KT: Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995, 73, 405-412.
5. Rao LVM, Nordfang O, Hoang A.D., Pendurthi UR: Mechanism of antithrombin III inhibition of factorVIIa/tissue factor activity on cell surfaces: comparison with tissue factor pathway inhibitor/factor Xa - induced inhibition of factorVIIa/tissue factor activity. Blood 1995, 85, 121-129.
6. Kyrle PA: Venous thrombosis: who should be screened for thrombophilia in 2014? Pol Arch Med Wewn 2014, 124, 65-69.
7. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci P.M., De Stefano V, Palareti G, Finazzi G., Baudo F, Quintavalla R: Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999, 19, 1026-1033.
8. Sanson BJ, Simioni P, Tormene D., Moia M, Friederich PW, Huisman M.V., Prandoni P., Bura A, Rejto L, Wells P., Mannucci PM, Girolami A, Büller HR, Prins MH: The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999, 94, 3702-3706.
9. Dykes AC, Walker ID, McMahon A.D., Islam SI, Tait RC: A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001, 113, 636-341.
10. Tait RC, Walker ID, Islam S.I., McCall F., Conkie JA, Mitchell R, Davidson JF: Influence of demographic factors in antithrombin III activity in a healthy population. Br J Haematol 1993, 84, 476-480.
11. Dolan G, Neal K, Cooper P., Brown P, Preston FE: Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994, 86, 798-803.
12. Rodeghiero F, Tosetto A: The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen - relationship with physiological variables and establishment of reference ranges. Thromb Haemost 1996, 76, 226-233.
13. Boerger LM, Morris PC, Thurnau G.R., Esmon CT, Comp PC: Oral contraceptives and gender affect protein S status. Blood 1987, 69, 692-694.
14. MacCallum PK, Cooper JA, Martin J, Howarth D.J., Meade TW, Miller GJ: Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998, 102, 609-615.
15. Franchi F, Biguzzi E, Martinelli I., Bucciarelli P, Palmucci C, D'Agostino S, Peyvandi F: Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res 2013, 132, 152-157.
16. Conlan MG, Folsom AR, Finch A, Davis C.E., Sorlie P., Wu KK: Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993, 70, 762-767.
17. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H., Lane DA, Morrison CE: Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997, 97, 785-797.
18. Assmann G, Schulte H: The importance of triglycerides: results from the Prospective Cardiovascular Münster (PROCAM) Study. Eur J Epidemiol 1992, 8, 99-103.
19. Han KH, Hong KH, Park J.H., Ko J., Kang DH, Choi KJ: C-reactive protein promotes monocyte chemoattractant protein-1-mediated Chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004, 109, 2566-25671.
20. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107, 398-404.
21. Cermak J, Key NS, Bach R.R., Balla J., Jacob HS, Vercellotti GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82, 513-520.
22. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005, 13, 417-430.
23. Owczarek D, Cibor D, Salapa K., Cies̈la A, Glowacki M.K., Pocztar H., Mach TH: Anti-inflammatory and anticoagulant properties of the protein C system in inflammatory bowel disease. Pol Arch Med Wewn 2012, 122, 209-216.
24. Kroll MH: Evaluating interference caused by lipemia. Clin Chem 2004, 50, 1968-1969.
25. Tate J, Ward G: Interferences in immunoassay. Clin Biochem Rev 2004, 25, 105-120.
26. Lippi G, Plebani M, Favaloro EJ: Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013, 39, 258-266.
27. Nikolac N: Lipemia: causes, interference mechanisms, detection and management. Biochem Med (Zagreb) 2014, 24, 57-67.
28. Kim JA, Kim JE, Song S.H., Kim HK: Influence of blood lipids on global coagulation test results. Ann Lab Med 2015, 35, 15-21.
29. Sola E, Navarro S, Medina P., Vayá A, Estellés A, Hernández-Mijares A, España F: Activated protein C levels in obesity and weight loss influence. Thromb Res 2009, 123, 697-700.
30. DePergola G, Pannacciulli N: Coagulation and fibrinolys is abnormalities in obesity. J Endocrinol Invest 2002, 25, 899-904.